Tetrahydroberberine

Tetrahydroberberine

SCHEMBL4922203

CI.COc1ccc2c(c1OC)CN1CCc3cc4c(cc3C1C2)OCO4

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F3 P13726 11/20 0.96
DRD1 P21728 9/20 0.96
DRD2 P14416 6/20 0.96
CYP3A4 P08684 3/20 0.96
DRD5 P21918 3/20 0.96
DRD3 P35462 3/20 0.96
CYP1A2 P05177 2/20 0.96
CYP2D6 P10635 2/20 0.96
CYP2C19 P33261 2/20 0.96
DRD4 P21917 2/20 0.96
LMNA P02545 2/20 0.96
ADRA1A P35348 1/20 0.96
MEN1 O00255 1/20 0.96
KMT2A Q03164 1/20 0.96
HTR1A P08908 2/20 0.76
ALOX15 P16050 1/20 0.76
HIF1A Q16665 1/20 0.76
HSD17B10 Q99714 1/20 0.76
KDM4E B2RXH2 1/20 0.76
GAA P10253 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrahydroberberine SCHEMBL30302597 0.98 F3 (1.00) F3DRD1DRD2CYP3A4DRD5
Tetrahydroberberine SCHEMBL14184002 0.98 F3 (1.00) F3DRD1DRD2CYP3A4DRD5
Tetrahydroberberine SCHEMBL2786492 0.98 F3 (1.00) F3DRD1DRD2CYP3A4DRD5
Tetrahydroberberine SCHEMBL232164 0.98 F3 (1.00) F3DRD1DRD2CYP3A4DRD5
Canadine SCHEMBL29365824 0.98 F3 (1.00) F3DRD1DRD2CYP3A4DRD5
Canadine SCHEMBL432394 0.98 F3 (1.00) F3DRD1DRD2CYP3A4DRD5
Tetrahydroberberine SCHEMBL30484836 0.98 F3 (1.00) F3DRD1DRD2CYP3A4DRD5
Tetrahydroberberine SCHEMBL3320124 0.97 F3 (0.98) F3DRD1DRD2CYP3A4DRD5
SCHEMBL2742547 0.89 F3 (0.83) F3DRD1DRD2CYP3A4DRD5
SCHEMBL2742464 0.89 F3 (0.83) F3DRD1DRD2CYP3A4DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080124404-A1 Hypolipidemic and/or hypocholesteremic compounds obtainable from the goldenseal plant NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-05-29 US disclosed
EP-0872903-B1 Method for making hydrogen storage alloy powder and electrode comprising the alloy powder SHINETSU CHEMICAL CO (JP) 2001-10-04 EP disclosed
US-6277519-B1 QUENCHING AN ALLOY MELT; COMMINUTION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2001-08-21 US disclosed
EP-0872903-A1 Method for making hydrogen storage alloy powder and electrode comprising the alloy powder Shin-Etsu Chemical Co., Ltd. (JP) 1998-10-21 EP disclosed
US-4758639-A Process for production of vinyl polymer SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080124404-A1 Hypolipidemic and/or hypocholesteremic compounds obtainable from the goldenseal plant LIPA, HMGCR, LCAT F3 529/4885DRD1 2571/4885DRD2 3145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.